Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic, Genstruct Partner on Toxicology Screening

NEW YORK (GenomeWeb News) — Gene Logic and Genstruct will partner in an effort to market screening technologies that their pharmaceutical clients could use to test the potential toxicity of various compounds, the firms said today in a joint statement.

Under the collaboration, Gene Logic will offer its toxicology databases and data on specific compounds for preclinical and clinical research to pharmaceutical, biotechnology, consumer products and other industries, the company said. Genstruct will apply its Causal Network Modeling platform to create network models that capture toxicity potential of compounds.

The companies also will conduct co-marketing initiatives for each others' products. They also said that they intend to collaborate on personalized oncology therapy.

Genstruct President and CEO Keith Elliston, who formerly served as CSO of Gene Logic, said in a statement that the partners plan to generate gene expression data from patient tumors, which will be analyzed using Genstruct's systems biology platform. The information derived from the analysis could be used by physicians to devise optimal therapy for each patient, he said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.